INNOVIVA, INC. Increase (Decrease) in Long-term Receivables, Current
INNOVIVA, INC. (INVA) reported Increase (Decrease) in Long-term Receivables, Current of $1.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent · last filed 2026-08-05
- INNOVIVA, INC. increase (decrease) in long-term receivables, current for the quarter ending 2026-06-30 was $1.17M, a 80.77% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in long-term receivables, current for the quarter ending 2026-03-31 was $271.00K.
- INNOVIVA, INC. increase (decrease) in long-term receivables, current for the quarter ending 2025-06-30 was $6.07M.
- INNOVIVA, INC. increase (decrease) in long-term receivables, current for the quarter ending 2025-03-31 was -$4.71M.
- INNOVIVA, INC. increase (decrease) in long-term receivables, current for fiscal 2025 was -$7.62M.
- INNOVIVA, INC. increase (decrease) in long-term receivables, current for fiscal 2024 was -$3.65M, a 124.40% decline from fiscal 2023.
- INNOVIVA, INC. increase (decrease) in long-term receivables, current for fiscal 2023 was $14.95M.
| Period end | Increase (Decrease) in Long-term Receivables, Current 3 month | Increase (Decrease) in Long-term Receivables, Current 6 month | Increase (Decrease) in Long-term Receivables, Current 12 month |
|---|---|---|---|
| 2026-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.44M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $271.00K 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | -$7.62M 10-K · filed 2026-02-25 | ||
| 2025-06-30 | $6.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.36M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | -$4.71M 10-Q · filed 2026-05-06 | ||
| 2024-12-31 | -$3.65M 10-K · filed 2026-02-25 | ||
| 2023-12-31 | $14.95M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |